Aardvark Therapeutics (NASDAQ:AARD) Coverage Initiated at Royal Bank of Canada

Investment analysts at Royal Bank of Canada assumed coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a report released on Monday, Marketbeat.com reports. The firm set an “outperform” rating and a $21.00 price target on the stock. Royal Bank of Canada’s price target would suggest a potential upside of 101.54% from the stock’s current price.

Separately, Cantor Fitzgerald started coverage on Aardvark Therapeutics in a research note on Monday. They issued an “overweight” rating and a $50.00 price target for the company.

Aardvark Therapeutics Price Performance

NASDAQ AARD opened at $10.42 on Monday. Aardvark Therapeutics has a twelve month low of $9.21 and a twelve month high of $19.58.

Insider Activity

In other Aardvark Therapeutics news, CFO Nelson Sun purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were bought at an average price of $16.00 per share, with a total value of $160,000.00. Following the completion of the purchase, the chief financial officer now directly owns 99,484 shares in the company, valued at $1,591,744. This trade represents a 11.18 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Tien-Li Lee acquired 16,542 shares of the company’s stock in a transaction on Friday, February 14th. The stock was acquired at an average cost of $16.00 per share, with a total value of $264,672.00. Following the completion of the purchase, the chief executive officer now directly owns 1,496,175 shares in the company, valued at approximately $23,938,800. This represents a 1.12 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.